Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate

被引:45
作者
Maldonado, Rafael [1 ]
机构
[1] Univ Pompeu Fabra, Lab Neurofarmacol, PRBB, Dept Ciencies Expt & Salut, Barcelona 08003, Spain
关键词
attention-deficit hyperactivity disorder; Concerta (R); Equasym XL (R); Medikinet Retard (R); Metadate CD (R); methylphenidate; pharmacokinetics; Ritalin LA (R); ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; LONG-ACTING METHYLPHENIDATE; ONCE-A-DAY; DEFICIT HYPERACTIVITY DISORDER; OROS METHYLPHENIDATE; DOUBLE-BLIND; LABORATORY SCHOOL; CHILDREN; ADHD; PLACEBO;
D O I
10.1517/17425255.2013.786041
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder of which the main features are inattention, hyperactivity and impulsivity. Methylphenidate (MPH) is the mainstay of treatment, but its short duration of action and consequent need for multiple administrations has been problematic for children attending school. Extended-release (ER) formulations have been developed to help overcome the drawbacks associated with immediate-release (IR) preparations. Areas covered: This review focuses on the pharmacokinetics of ER MPH formulations (Concerta (R), Equasym XL (R)/Metadate CD (R), Medikinet Retard (R) and Ritalin LA (R)). It also attempts to align the properties of each agent with available clinical findings in children/adolescents with ADHD. Expert opinion: In the author's opinion, Concerta, Equasym XL/Metadate CD, Medikinet Retard and Ritalin LA offer the convenience of once-daily administration with absorption characteristics resembling two or three times daily dosing with IR MPH preparations. All formulations produce plasma concentrations necessary to maintain symptom control during school time in children with ADHD. However, their pharmacokinetic profiles differ with respect to peak plasma levels and the rate at which peak levels are attained and decline. These differences may provide physicians with the opportunity to prescribe a formulation best suited to the symptom profile of individual patients. Additional clinical research is required to clarify further the relative merits of these ER formulations with the goal of enabling
引用
收藏
页码:1001 / 1014
页数:14
相关论文
共 66 条
  • [1] Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study
    Adler, Lenard A.
    Zimmerman, Brenda
    Starr, H. Lynn
    Silber, Steve
    Palumbo, Joseph
    Orman, Camille
    Spencer, Thomas
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (03) : 239 - 247
  • [2] [Anonymous], 2010, CONC PRESCR INF
  • [3] [Anonymous], VALUE HLTH, DOI DOI 10.1046/J.1524-4733.2001.40202-196.X
  • [4] [Anonymous], 2008, NICE clinical guideline, V72
  • [5] [Anonymous], CAN ADHD PRACT GUID
  • [6] Long-acting medications for the hyperkinetic disorders -: A systematic review and European treatment guideline
    Banaschewski, Tobias
    Coghill, David
    Santosh, Paramala
    Zuddas, Alessandro
    Asherson, Philip
    Buitelaar, Jan
    Danckaerts, Marina
    Doepfner, Manfred
    Faraone, Stephen V.
    Rothenberger, Aribert
    Sergeant, Joseph
    Steinhausen, Hans-Christoph
    Sonuga-Barke, Edmund J. S.
    Taylor, Eric
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2006, 15 (08) : 476 - 495
  • [7] Efficacy and Safety of Ritalin® LA™, a New, Once Daily, Extended-Release Dosage Form of Methylphenidate, in Children with Attention Deficit Hyperactivity Disorder
    Joseph Biederman
    Declan Quinn
    Margaret Weiss
    Sabri Markabi
    Meredith Weidenman
    Kathryn Edson
    Goeril Karlsson
    Harald Pohlmann
    Sharon Wigal
    [J]. Pediatric Drugs, 2003, 5 (12) : 833 - 841
  • [8] Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants
    Buitelaar, Jan
    Medori, Rossella
    [J]. EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2010, 19 (04) : 325 - 340
  • [9] Osmotic, controlled-release methylphenidate for the treatment of ADHD
    Coghill, David
    Seth, Sarah
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (15) : 2119 - 2138
  • [10] Impact of attention-deficit/hyperactivity disorder on the patient and family: Results from a European survey
    Coghill D.
    Soutullo C.
    d'Aubuisson C.
    Preuss U.
    Lindback T.
    Silverberg M.
    Buitelaar J.
    [J]. Child and Adolescent Psychiatry and Mental Health, 2 (1)